P. Kil

Duration of Androgen Suppression in the Treatment of Prostate Cancer

M. Bolla, Theodorus M. de Reijke, Geertjan van Tienhoven et al. · New England Journal of Medicine · 2009 · 966 citations · Full text

Medicine, Oncology, Urology +14

Effects of age and comorbidity on treatment and survival of patients with muscle‐invasive bladder cancer

Catharina A. Goossens‐Laan, Anna M. Leliveld, Rob H.A. Verhoeven et al. · International Journal of Cancer · 2014 · 78 citations · Full text

Medicine, Oncology, Surgery +14

Prostate cancer: Trends in incidence, survival and mortality in the Netherlands, 1989–2006

R.G.H.M. Cremers, Henrike E. Karim‐Kos, Saskia Houterman et al. · European Journal of Cancer · 2010 · 72 citations

Medicine, Oncology, Urology +13

The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population‐based study

Piet N. Post, Bettina E. Hansen, P. Kil et al. · British Journal of Urology · 2001 · 69 citations

Medicine, Oncology, Urology +17

Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—Results of the randomized EORTC Phase III trial 22961

M. Bolla, Geertjan van Tienhoven, Theodorus M. de Reijke et al. · Journal of Clinical Oncology · 2007 · 58 citations

Medicine, Oncology, Radiation Oncology +17